Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:04 AM
Study NCT ID:
NCT00004938
Status:
COMPLETED
Last Update Posted:
2006-06-09
First Post:
2000-02-24
Brief Title:
Phase II Study of Fluconazole for Lymphocutaneous and Visceral Sporotrichosis
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
Office of Rare Diseases ORD
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2000-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
OBJECTIVE
I Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis
I Evaluate the efficacy of fluconazole in patients with lymphocutaneous or visceral sporotrichosis
Detailed Description:
PROTOCOL OUTLINE
Patients are treated with daily oral fluconazole for up to 24 months Follow-up continues for at least 1 year
Patients are treated with daily oral fluconazole for up to 24 months Follow-up continues for at least 1 year
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NIAID-MSG-11815 | None | None | None |